Syndax Pharmaceuticals (SNDX) Assets (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Assets of $472.7 million for Q1 2026, down 26.23% year-over-year from $640.7 million in Q1 2025, and down 10.77% quarter-over-quarter from $529.7 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Assets (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Assets history runs 12 years deep, the most recent figure standing at $472.7 million for Q1 2026.
- In Q1 2026, Assets fell 26.23% year-over-year to $472.7 million; the TTM figure through Mar 2026 stood at $472.7 million (down 26.23% YoY), while the FY2025 annual figure was $529.7 million, down 26.92% from the prior year.
- Assets for Q1 2026 stood at $472.7 million, down from $529.7 million in the prior quarter.
- The five-year high for Assets was $724.8 million in Q4 2024, with the low at $359.7 million in Q3 2022.
- The 5-year median for Assets is $476.9 million (2024), against an average of $503.0 million.
- The sharpest annual moves came in 2022 and 2025: Assets soared 54.5% in 2022, then retreated 26.92% in 2025.
- Syndax Pharmaceuticals' Assets stood at $497.2 million in 2022, then increased by 23.26% to $612.9 million in 2023, then rose by 18.26% to $724.8 million in 2024, then declined by 26.92% to $529.7 million in 2025, then retreated by 10.77% to $472.7 million in 2026.
- Business Quant data shows SNDX's Assets at $472.7 million in Q1 2026, $529.7 million in Q4 2025, and $551.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn | 703.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 703.65 Mn |
| Mar 31, 2026 | 472.67 Mn |
| Dec 31, 2025 | 529.71 Mn |
| Sep 30, 2025 | 551.79 Mn |
| Jun 30, 2025 | 596.15 Mn |
| Mar 31, 2025 | 640.71 Mn |
| Dec 31, 2024 | 724.82 Mn |
| Sep 30, 2024 | 425.81 Mn |
| Jun 30, 2024 | 476.95 Mn |
| Mar 31, 2024 | 543.03 Mn |
| Dec 31, 2023 | 612.88 Mn |
| Sep 30, 2023 | 399.22 Mn |
| Jun 30, 2023 | 431.34 Mn |
| Mar 31, 2023 | 459.83 Mn |
| Dec 31, 2022 | 497.24 Mn |
| Sep 30, 2022 | 359.69 Mn |
| Jun 30, 2022 | 406.44 Mn |
| Mar 31, 2022 | 422.22 Mn |
| Dec 31, 2021 | 449.66 Mn |
| Sep 30, 2021 | 239.50 Mn |